- ICH GCP
- USA klinikai vizsgálatok nyilvántartása
- Klinikai vizsgálat NCT05137548
A Drug-Drug Interaction Study Between ATI-2173 and Tenofovir Disoproxil Fumarate in Healthy Subjects
A Phase 1, Open-label, 2-cohort, Multiple Dose, Drug-drug Interaction, Safety and Tolerability, Fixed-sequence Study to Investigate the Potential Interaction Between ATI-2173 When Coadministered With Tenofovir Disoproxil Fumarate in Healthy Subjects
A tanulmány áttekintése
Állapot
Körülmények
Beavatkozás / kezelés
Tanulmány típusa
Beiratkozás (Tényleges)
Fázis
- 1. fázis
Kapcsolatok és helyek
Tanulmányi helyek
-
-
Quebec
-
Montréal, Quebec, Kanada, H3P 3P1
- Altasciences
-
-
Részvételi kritériumok
Jogosultsági kritériumok
Tanulmányozható életkorok
Egészséges önkénteseket fogad
Tanulmányozható nemek
Leírás
Inclusion Criteria:
- Provision of signed and dated Informed Consent Form (ICF)
- Stated willingness to comply with all study procedures (including ability and willingness to abstain from alcohol from 48 hours prior to the first study drug administration until discharge) and availability for the duration of the study
- Healthy adult male or female
- Aged between 18 and 59 years, inclusive
- Body mass index (BMI) within 18.5 kg/m2 to 30.0 kg/m2, inclusively
- Non- or ex-smoker (an ex-smoker is defined as someone who completely stopped using nicotine products for at least 180 days prior to the first study drug administration)
- Suitable veins for cannulation or repeated venipuncture as assessed by an Investigator at Screening Have no clinically significant diseases captured in the medical history or evidence of clinically significant findings on the physical examination (including vital signs) and/or ECG, as determined by an Investigator
9. Agrees to abstain from blood or plasma donation from the Screening visit until 3 months after the last study drug administration 10. If female, must meet one of the following criteria:
Is of childbearing potential and agrees to use an acceptable contraceptive method. Acceptable contraceptive methods include:
- Abstinence from heterosexual intercourse from Screening through to at least 60 days after the last dose of the study drug
- Male partner vasectomized at least 180 days prior to Screening
- Double-barrier method (eg, male condom, spermicide and diaphragm or cervical cap used simultaneously) from Screening through to at least 30 days after the last dose of the study drug
- One of the following contraceptive methods with a barrier method (eg, male condom) from at least 28 days prior to the first study drug administration through to at least 60 days after the last dose of the study drug:
- Systemic contraceptives (combined birth control pills, injectable/implant/insertable hormonal birth control products, transdermal patch)
- Intrauterine device (with or without hormones) If systemic contraceptives are used, must agree to use an additional acceptable non-hormonal method during the study and for at least 60 days after the last dose of the study drug Or
Is of non-childbearing potential, defined as surgically sterile (ie, has undergone complete hysterectomy, bilateral oophorectomy, or tubal ligation/occlusion) or in a postmenopausal state (at least 1 year without menses without an alternative medical condition prior to Screening), as confirmed by follicle-stimulating hormone levels (≥ 40 mIU/mL).
11. A male study subject that engages in sexual activity that has the risk of pregnancy must:
- Agree to use a double-barrier method (eg, male condom, spermicide and diaphragm or cervical cap used simultaneously) or be abstinent from heterosexual intercourse from Screening to at least 90 days after the last study drug administration or be unable to procreate; defined as surgically sterile (i.e. has undergone a vasectomy at least 180 days prior to Screening) AND
- Agree to not donate sperm during the study and for at least 90 days after the last study drug administration 12. Body weight ≥35 kg (≥77 lb)
Exclusion Criteria:
- Female who is lactating
- Female who is pregnant according to the pregnancy test at Screening or prior to the first study drug administration
- Pulse rate less than 50 beats per minute or more than 100 beats per minute at Screening or prior to the first study drug administration unless deemed not clinically significant by the Investigator
- Blood pressure below 100/60 mmHg or higher than 140/90 mmHg at Screening or prior to the first study drug administration unless deemed not clinically significant by the Investigator
- History of hypersensitivity to ATI-2173, clevudine, tenofovir, or any related products (including excipients of the formulations) as well as severe hypersensitivity reactions (like angioedema) to any drugs
- Presence or history of significant gastrointestinal, liver or kidney disease, or surgery that may affect drug bioavailability including but not limited to cholecystectomy
- History of significant cardiovascular, pulmonary, hematologic, neurological, psychiatric, endocrine, immunologic or dermatologic disease, in the opinion of an Investigator
- Presence of clinically significant ECG abnormalities at Screening or prior to study drug administration, in the opinion of an Investigator
- Presence of clinically significant muscle disorders, myopathies or other forms of liver disease, in the opinion of an Investigator
- Estimated glomerular filtration rate (eGFR) < 80 mL/min/1.73 m2 using the Modification of Diet in Renal Disease (MDRD) equation at Screening or < 60 mL/min/1.73 m2 on Day -1
- Hemoglobin value below the lower limit of the reference laboratory at Screening or prior to study drug administration
- Unexplained persistent elevations of serum transaminases or creatine kinase (CK) levels at Screening or prior to study drug administration
- Maintenance therapy with any drug or significant history of drug dependency or alcohol abuse (> 3 units of alcohol per day, intake of excessive alcohol, acute or chronic)
- Any clinically significant illness in the 28 days prior to the first study drug administration
- Use of any prescription drugs (except systemic contraception and intrauterine devices) in the 30 days prior to the first study drug administration, that in the opinion of an Investigator would put into question the status of the participant as healthy
- Use of St. John's wort in the 30 days prior to the first study drug administration
- Use of quinine-containing products (eg, tonic water), grapefruit products, pomelo products, Seville orange products, including supplements containing Citrus aurantium or "bitter orange", in the 14 days prior to the first study drug administration
- Any history of latent or active tuberculosis
- Positive screening tuberculosis blood test
- Immunization with a COVID-19 vaccine in the 14 days prior to the first study drug administration
- Scheduled immunization with a COVID-19 vaccine (first or second dose) during the study that, in the opinion of an investigator, could potentially interfere with subject participation, subject safety, study results, or any other reason
- Positive test result for alcohol and/or drugs of abuse at Screening or prior to the first drug administration
- Positive test results for HIV-1/HIV-2 antibodies, hepatitis B surface antigen or hepatitis C antibody at Screening
- Any other clinically significant abnormalities in laboratory test results at Screening or prior to the first drug administration that would, in the opinion of an Investigator, increase the subject's risk of participation, jeopardize complete participation in the study, or compromise interpretation of study data.
- Inclusion in a previous group for this clinical study
- Participation in another clinical study with a non-biologic Investigational Product (IP) or new formulation of a marketed non-biologic drug in the 30 days prior to the first study drug administration
- Participation in another clinical study with a biologic (marketed or investigational) in the 90 days or 5 half-lives (whichever is longer) prior to the first study drug administration
- Donation of 50 mL or more of blood in the 28 days prior to the first study drug administration
- Donation of 500 mL or more of blood (Canadian Blood Services, Hema-Quebec, clinical studies, etc.) in the 56 days prior to the first study drug administration
- History of pathologic fracture or other risk factors for osteoporosis or bone loss
Tanulási terv
Hogyan készül a tanulmány?
Tervezési részletek
- Elsődleges cél: Kezelés
- Kiosztás: Nem véletlenszerű
- Beavatkozó modell: Szekvenciális hozzárendelés
- Maszkolás: Nincs (Open Label)
Fegyverek és beavatkozások
Résztvevő csoport / kar |
Beavatkozás / kezelés |
---|---|
Kísérleti: ATI-2173.
ATI-2173
|
ATI-2173 is a liver-targeted phosphoramidate oral prodrug of clevudine designed to enhance anti-HBV activity while decreasing systemic exposure to clevudine.
It will be dosed as a capsule by mouth
|
Kísérleti: Tenofovir Disoproxil Fumarate
Tenofovir disoproxil fumarate
|
Tenofovir is an oral nucleotide analogue reverse transcriptase inhibitor used for chronic hepatitis B virus.
It will be dosed as a tablet by mouth
Más nevek:
|
Mit mér a tanulmány?
Elsődleges eredményintézkedések
Eredménymérő |
Időkeret |
---|---|
Cmax of ATI-2173, clevudine, and M1 in plasma
Időkeret: Through end of study, approximately 3 months
|
Through end of study, approximately 3 months
|
AUCtau of ATI-2173, clevudine, and M1 in plasma
Időkeret: Through end of study, approximately 3 months
|
Through end of study, approximately 3 months
|
AUC0-t of ATI-2173, clevudine, and M1 in plasma
Időkeret: Through end of study, approximately 3 months
|
Through end of study, approximately 3 months
|
Cmax of tenofovir
Időkeret: Through end of study, approximately 3 months
|
Through end of study, approximately 3 months
|
Cmin,ss of tenofovir
Időkeret: Through end of study, approximately 3 months
|
Through end of study, approximately 3 months
|
AUC0-tau of tenofovir
Időkeret: Through end of study, approximately 3 months
|
Through end of study, approximately 3 months
|
AUC0-t of tenofovir
Időkeret: Through end of study, approximately 3 months
|
Through end of study, approximately 3 months
|
Másodlagos eredményintézkedések
Eredménymérő |
Időkeret |
---|---|
Number of Adverse Events
Időkeret: Through end of study, approximately 3 months
|
Through end of study, approximately 3 months
|
Egyéb eredményintézkedések
Eredménymérő |
Időkeret |
---|---|
Plasma trough concentrations of tenofovir, ATI-2173, clevudine, and M1
Időkeret: Days 18, 19, 20 and 21
|
Days 18, 19, 20 and 21
|
Együttműködők és nyomozók
Szponzor
Tanulmányi rekorddátumok
Tanulmány főbb dátumok
Tanulmány kezdete (Tényleges)
Elsődleges befejezés (Tényleges)
A tanulmány befejezése (Tényleges)
Tanulmányi regisztráció dátumai
Először benyújtva
Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak
Első közzététel (Tényleges)
Tanulmányi rekordok frissítései
Utolsó frissítés közzétéve (Tényleges)
Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak
Utolsó ellenőrzés
Több információ
A tanulmányhoz kapcsolódó kifejezések
További vonatkozó MeSH feltételek
Egyéb vizsgálati azonosító számok
- ANTT102
Terv az egyéni résztvevői adatokhoz (IPD)
Tervezi megosztani az egyéni résztvevői adatokat (IPD)?
Gyógyszer- és eszközinformációk, tanulmányi dokumentumok
Egy amerikai FDA által szabályozott gyógyszerkészítményt tanulmányoz
Egy amerikai FDA által szabályozott eszközterméket tanulmányoz
Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .
Klinikai vizsgálatok a Kábítószer-kölcsönhatás
-
Washington State UniversityNational Center for Complementary and Integrative Health (NCCIH)BefejezveInteraction Drug FoodEgyesült Államok
-
Astellas Pharma Europe B.V.BefejezveEgészséges alanyok | Farmakokinetika | DDI (Drug-Drug Interaction)Németország
-
Washington State UniversityNational Center for Complementary and Integrative Health (NCCIH); Office of Dietary...Aktív, nem toborzóInteraction Drug FoodEgyesült Államok
-
Washington State UniversityNational Center for Complementary and Integrative Health (NCCIH)BefejezveInteraction Drug FoodEgyesült Államok
-
Radboud University Medical CenterAmgenBefejezve
-
Centre de recherche du Centre hospitalier universitaire...Lallemand Health SolutionsBefejezve
-
Yinyi(Liaoning) Biotech Co., Ltd.Befejezve
-
Chinese University of Hong KongBefejezveKOMBO Állapot | STIGMA állapot | INTERACT Állapot | VEZÉRLÉS állapotaHong Kong
-
Hospital de Clinicas de Porto AlegreFederal University of Rio Grande do SulIsmeretlenÖregedés | Interaction Drug Food | Primer hypothyreosisBrazília
-
Boston UniversityUniversity of Florida; WestatVisszavontTuberculosis Multi Drug Resistant Active
Klinikai vizsgálatok a ATI-2173 50 mg
-
Antios Therapeutics, IncMegszűntKrónikus hepatitis bEgyesült Államok
-
9 Meters Biopharma, Inc.MegszűntRövid bél szindrómaEgyesült Államok
-
HK inno.N CorporationBefejezveEgészségesKoreai Köztársaság
-
Zydus Lifesciences LimitedToborzás
-
ViiV HealthcareGlaxoSmithKline; Janssen PharmaceuticalsBefejezveFertőzés, emberi immunhiány vírusEgyesült Államok
-
Sihuan Pharmaceutical Holdings Group Ltd.Ismeretlen
-
Guangdong Zhongsheng Pharmaceutical Co., Ltd.BefejezveSzilárd daganat | Idiopátiás tüdőfibrózis (IPF)Kína
-
Alcon ResearchBefejezveNeovaszkuláris korral összefüggő makuladegeneráció
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Ismeretlen